Your browser doesn't support javascript.
loading
TLCD1 and TLCD2 regulate cellular phosphatidylethanolamine composition and promote the progression of non-alcoholic steatohepatitis.
Petkevicius, Kasparas; Palmgren, Henrik; Glover, Matthew S; Ahnmark, Andrea; Andréasson, Anne-Christine; Madeyski-Bengtson, Katja; Kawana, Hiroki; Allman, Erik L; Kaper, Delaney; Uhrbom, Martin; Andersson, Liselotte; Aasehaug, Leif; Forsström, Johan; Wallin, Simonetta; Ahlstedt, Ingela; Leke, Renata; Karlsson, Daniel; González-King, Hernán; Löfgren, Lars; Nilsson, Ralf; Pellegrini, Giovanni; Kono, Nozomu; Aoki, Junken; Hess, Sonja; Sienski, Grzegorz; Pilon, Marc; Bohlooly-Y, Mohammad; Maresca, Marcello; Peng, Xiao-Rong.
Afiliação
  • Petkevicius K; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. kasparas.petkevicius@astrazeneca.com.
  • Palmgren H; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. kasparas.petkevicius@astrazeneca.com.
  • Glover MS; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Ahnmark A; Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden.
  • Andréasson AC; Dynamic Omics, Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Madeyski-Bengtson K; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Kawana H; Bioscience Cardiovascular, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Allman EL; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Kaper D; Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
  • Uhrbom M; Advanced Research & Development Programs for Medical Innovation (AMED-LEAP), Tokyo, Japan.
  • Andersson L; Dynamic Omics, Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Aasehaug L; Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden.
  • Forsström J; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Wallin S; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Ahlstedt I; Bioscience Cardiovascular, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Leke R; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Karlsson D; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • González-King H; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Löfgren L; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Nilsson R; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Pellegrini G; Bioscience Cardiovascular, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Kono N; Translational Science and Experimental Medicine, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Aoki J; Translational Science and Experimental Medicine, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Hess S; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Sienski G; Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
  • Pilon M; Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
  • Bohlooly-Y M; Advanced Research & Development Programs for Medical Innovation (AMED-LEAP), Tokyo, Japan.
  • Maresca M; Dynamic Omics, Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Peng XR; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Nat Commun ; 13(1): 6020, 2022 10 14.
Article em En | MEDLINE | ID: mdl-36241646
ABSTRACT
The fatty acid composition of phosphatidylethanolamine (PE) determines cellular metabolism, oxidative stress, and inflammation. However, our understanding of how cells regulate PE composition is limited. Here, we identify a genetic locus on mouse chromosome 11, containing two poorly characterized genes Tlcd1 and Tlcd2, that strongly influences PE composition. We generated Tlcd1/2 double-knockout (DKO) mice and found that they have reduced levels of hepatic monounsaturated fatty acid (MUFA)-containing PE species. Mechanistically, TLCD1/2 proteins act cell intrinsically to promote the incorporation of MUFAs into PEs. Furthermore, TLCD1/2 interact with the mitochondria in an evolutionarily conserved manner and regulate mitochondrial PE composition. Lastly, we demonstrate the biological relevance of our findings in dietary models of metabolic disease, where Tlcd1/2 DKO mice display attenuated development of non-alcoholic steatohepatitis compared to controls. Overall, we identify TLCD1/2 proteins as key regulators of cellular PE composition, with our findings having broad implications in understanding and treating disease.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosfatidiletanolaminas / Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosfatidiletanolaminas / Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suécia